Dual PI3K/mTOR inhibition in PIK3CA mutant pancreatic cancers

被引：0
|
作者：
Payne, Susan [1 ]
Depke, Mitchell [1 ]
Yueh, Alex [1 ]
Sharick, Joseph T. [2 ]
Favreau, Peter F. [2 ]
Pasch, Cheri A. [1 ]
Clipson, Linda [1 ]
Matkowskyj, Kristina A. [1 ]
Skala, Melissa [2 ]
Deming, Dustin A. [1 ]
机构：
[1] Univ Wisconsin, Madison, WI USA
[2] Morgridge Inst Res, Madison, WI USA
来源：
CANCER RESEARCH | 2018年 / 78卷 / 13期
关键词：
D O I：
10.1158/1538-7445.AM2018-3472
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
3472
引用
收藏
页数：2
相关论文
共 50 条
  • [1] Dual PI3K/mTOR inhibition as a treatment strategy for PIK3CA and APC mutant colorectal cancers
    Payne, Susan
    Foley, Tyler
    Pasch, Cheri
    Yueh, Alexander
    Korkos, Demetra
    Van De Hey, Dana
    Clipson, Linda
    Deming, Dustin
    CANCER RESEARCH, 2016, 76
  • [2] Treatment of PIK3CA and APC mutant colorectal cancers with dual PI3K/mTOR inhibition.
    Tyler, Foley
    Payne, Susan
    Yeuh, Alexander
    Van DeHey, Dana
    Pasch, Cheri
    Clipson, Linda
    Matkowskyj, Kristina
    Deming, Dustin A.
    JOURNAL OF CLINICAL ONCOLOGY, 2015, 33 (15)
  • [3] Dual PI3K/mTOR Inhibition in Colorectal Cancers with APC and PIK3CA Mutations
    Foley, Tyler M.
    Payne, Susan N.
    Pasch, Cheri A.
    Yueh, Alex E.
    Van De Hey, Dana R.
    Korkos, Demetra P.
    Clipson, Linda
    Maher, Molly E.
    Matkowskyj, Kristina A.
    Newton, Michael A.
    Deming, Dustin A.
    MOLECULAR CANCER RESEARCH, 2017, 15 (03) : 317 - 327
  • [4] Differential response to a dual PI3K/mTOR inhibitor in PIK3CA mutant urothelial cancer patient derived xenografts
    Elbanna, May F.
    Ciamporcero, Eric
    Adelaiye, Remi
    Orillion, Ashley
    Chintala, Sreenivasulu
    Pili, Roberto
    CANCER RESEARCH, 2016, 76
  • [5] PIK3CA Mutations in Patients with Advanced Cancers Treated with PI3K/AKT/mTOR Axis Inhibitors
    Janku, Filip
    Tsimberidou, Apostolia M.
    Garrido-Laguna, Ignacio
    Wang, Xuemei
    Luthra, Rajyalakshmi
    Hong, David S.
    Naing, Aung
    Falchook, Gerald S.
    Moroney, John W.
    Piha-Paul, Sarina A.
    Wheler, Jennifer J.
    Moulder, Stacy L.
    Fu, Siqing
    Kurzrock, Razelle
    MOLECULAR CANCER THERAPEUTICS, 2011, 10 (03) : 558 - 565
  • [6] PIK3CA Mutations PREDICT RESPONSE TO PI3K/AKT/mTOR INHIBITORS
    不详
    CANCER DISCOVERY, 2012, 2 (03) : 205 - 205
  • [7] Activation of the MACC1/PIM/cMyc axis confers resistance to PI3K/mTOR inhibition in PIK3CA mutant NSCLC
    Moore, Gillian
    Elbai, Samira
    Heavey, Susan
    Finn, Stephen
    O'Neill, Michael
    Gately, Kathy
    MOLECULAR CANCER RESEARCH, 2020, 18 (10) : 48 - 48
  • [8] Mutant PIK3CA-mediated pancreatic tumorigenesis and the response to PI3K pathway inhibition.
    Payne, Susan
    Maher, Molly
    Nguyen Tran
    Van DeHey, Dana
    Tyler, Foley
    Yeuh, Alexander
    Leystra, Alyssa A.
    Pasch, Cheri
    Clipson, Linda
    Matkowskyj, Kristina
    Deming, Dustin A.
    JOURNAL OF CLINICAL ONCOLOGY, 2015, 33 (15)
  • [9] PIK3CA mutations can initiate pancreatic tumorigenesis and are targetable with PI3K inhibitors
    S N Payne
    M E Maher
    N H Tran
    D R Van De Hey
    T M Foley
    A E Yueh
    A A Leystra
    C A Pasch
    J J Jeffrey
    L Clipson
    K A Matkowskyj
    D A Deming
    Oncogenesis, 2015, 4 : e169 - e169
  • [10] PIK3CA regulates development of diabetes retinopathy through the PI3K/Akt/mTOR pathway
    Guan, Ruijuan
    Kang, Zefeng
    Li, Ling
    Yan, Xin
    Gao, Tianpeng
    PLOS ONE, 2024, 19 (01):
12345